Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | RORB | Q92753 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27448738 | 0.84 | KCNQ2 (0.54) | RORCLPAR1LPAR3GRM5SMN1; SMN2 | |
| SCHEMBL9915925 | 0.80 | LPAR1 (0.52) | LPAR1KDM4CLPAR3 | |
| SCHEMBL29895998 | 0.77 | LPAR1 (0.51) | RORCLPAR1KDM4CLPAR3LRRK2 | |
| SCHEMBL896819 | 0.77 | MEN1 (0.57) | MCL1 | |
| SCHEMBL29896002 | 0.76 | GAA (0.57) | LPAR1LPAR3LRRK2SMN1; SMN2 | |
| SCHEMBL29895995 | 0.74 | LPAR1 (0.53) | RORCLPAR1LPAR3LRRK2GRM5 | |
| SCHEMBL4435014 | 0.74 | POLB (0.62) | SMN1; SMN2 | |
| SCHEMBL29895989 | 0.74 | LPAR1 (0.47) | RORCLPAR1LPAR3GRM5HCAR2 | |
| SCHEMBL15261910 | 0.73 | LPAR1 (0.45) | LPAR1LPAR3 | |
| SCHEMBL9915929 | 0.73 | LPAR1 (0.45) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | LPAR2, LPAR1, LPAR4 | RORC 551/4885LPAR1 2/4885KDM4C 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.